Serum adiponectin and metabolic profile in women with polycystic ovarian syndrome in relation to body mass index
DOI:
https://doi.org/10.18203/2320-6012.ijrms20220508Keywords:
Polycystic ovarian syndrome, Adiponectin, Metabolic profile, Body mass indexAbstract
Background: Polycystic ovarian syndrome is a common endocrine disorder which affects approximately 5-10% of women in reproductive age. It is both a reproductive endocrinopathy and a metabolic disorder.
Methods: 160 women aged 18 to 40 years attending obstetrics and gynaecology clinic at Federal medical centre, Owerri, Imo State Nigeria were recruited and divided into 2 groups (women diagnosed with PCOS using Rotterdam criteria and control) of 80 participants each. Anthropometric data were collected, and participants categorized into 3 based on BMI. Fasting blood samples was collected for biochemical analyses. Data were analyzed using the Statistical Package for Social Sciences SPSS version 23.0, and level of significance set at p<0.05.
Results: The mean serum levels of adiponectin and high density lipoprotein (HDL-C) were significantly lower while fasting plasma glucose, serum insulin, homeostatic model assessment for insulin resistance, total cholesterol, low density lipoprotein (LDL-C), very low density lipoprotein (VLDL-C) and triglyceride were significantly higher in women with PCOS when compared with the control (p<0.05) as well as in obese when compared with normal weight women with PCOS (p<0.05). BMI negatively correlated with serum adiponectin and HDL-C, but positively correlated with FPG, insulin, HOMA-IR, TC, TG, LDL-C and VLDL-C in women with PCOS (p<0.05).
Conclusions: This study highlights the prevalent biochemical and metabolic derangements in PCOS patients and was more evident in the obese and overweight patients. Early detection with subsequent application of preemptive measures including lifestyle modifications are therefore essential in the management of PCOS patients.
References
Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745-9.
Deswal R, Narwal V, Dang A,Pundir CS. The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. J Hum Reprod Sci. 2020;13(4): 261-71.
Aversa A, Sandro LV, Rocco R, Alessandra G, Nappi RE, Calogero AE, et al. Fundamental Concepts and Novel Aspects of Polycystic Ovarian Syndrome: Expert Consensus Resolutions. Front Endocrinol. 2020;11:516.
Vignesh JP, Mohan V. Polycystic ovary syndrome: A component of metabolic syndrome? J Postgrad Med. 2007;53:128-34.
Legro RS. Polycystic ovary syndrome and cardiovascular disease: A premature association? Endocr Rev. 2003;24:302-12.
Grundy SM, Cleeman JL, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-52.
Teede HJ, Joham AE, Paul E, Moran LJ, Loxton D, Jolley DJ, et al. Longitudinal weight gain in women identified with polycystic ovary syndrome: results of an observational study in young women. Obesity. 2013;21:1526-32.
Lindberg S, Jensen JS, Bjerre M, Frystyk J, Flyvbjerg A, Jeppesen J, et al. Low adiponectin levels at baseline and decreasing adiponectin levels over 10 years of follow-up predict risk of the metabolic syndrome. Diabetes Metab. 2017;43:134-9.
Demirci H, Yilmaz M, Ergun MA, Yurtcu E, Bukan N, Ayvaz G. Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance and clinical parameters. Gynecol Endocrinol. 2010;26:348-55.
Shirazi FKH, Khodamoradi Z, Jeddi M. Insulin resistance and high molecular weight adiponectin in obese and non-obese patients with polycystic ovarian syndrome (PCOS). BMC Endocr Disord. 2021;21:45.
Igwegbe AO, Eleje GU,Enechukwu CI. Polycystic Ovary Syndrome: A Review of Management Outcomes in a Low Resource Setting. J Women’s Health Issues Care. 2013;2:3.
Cochrane WG. Sampling techniques. 2nd ed. New York: John Wiley and Sons Inc; 1963.
Gowthami P, Kiranmayi VS, Rani BS, Suresh V,Vijayalakshmi DB. Study of serum adiponectin levels in women with polycystic ovary syndrome. Indian J Obstet Gynecol Res. 2019;6(3):288-92.
O'Connor A, Phelan N, Tun TK, BoranG, Gibney J, Roche HM. High molecular-Weight adiponectin is selectively reduced in women with polycystic ovary syndrome independent of body mass index and severity of insulin resistance. J Clin Endocrinol Metab. 2010;95(3):1378-85.
Wang T, Sha L, Li Y, Zhu L, Wang Z, Li K, et al. Plasma adiponectin levels and type 2 diabetes risk: a nested case-control study in a Chinese population and an updated meta-analysis. Sci Rep. 2018;8(1):406.
Zhang J, Xu JH, Qu QQ,Zhong GQ. Risk of Cardiovascular and Cerebrovascular Events in Polycystic Ovarian Syndrome Women: A Meta-Analysis of Cohort Studies. Front Cardiovasc Med. 2020;7:552421.
Al-Goblan AS, Al-Alfi MA, Khan, MZ. Mechanism linking diabetes mellitus and obesity. Diabet Metab Synd Obes Targets Ther. 2014;7:587-91.
Zhu JP, Teng YC, Zhou J, Lu W, Tao MF, Jia WP. Increased mean glucose levels in patients with polycystic ovary syndrome and hyperandrogenemia as determined by continuous glucose monitoring. Acta Obstet Gynecol Scand. 2013;92(2):165-71.
Veena HC, Reshmarani, Shilpa N. Altered blood glucose levels in polycystic ovary syndrome. Sch J Appl Med Sci. 2014;2(5F):1942-5.
Kheirollahi A, Teimouri M, Karimi M, Vatannejad A, Moradi N, Borumandnia N, et al. Evaluation of lipid ratios and triglyceride-glucose index as risk markers of insulin resistance in Iranian polycystic ovary syndrome women. Lipids Health Dis. 2020;19(1):235.
Rashidi H, Tafazoli M, Jalali MT, Mofrad AME. Serum lipid profile and insulin resistance in women with polycystic ovary syndrome (PCOS). J Diab Metab Disord Control. 2018;5(3):107-11.
Linder S, Abu-Omar K, Geidl W, Messing S, Sarshar M, Reimers AK, et al. Physical inactivity in healthy, obese, and diabetic adults in Germany: An analysis of related socio-demographic variables. PloS One. 2021;16(2):e0246634.
Ollila MM, Piltonen T, Puukka K, Ruokonen A, Järvelin MR, Tapanainen JS, et al. Weight Gain and Dyslipidemia in Early Adulthood Associate with Polycystic Ovary Syndrome: Prospective Cohort Study. J Clin Endocrinol Metab. 2016;101(2):739-47.
Demir I, Guler A, Alarslan P, Isil AM, Ucman O, Aslanipour B, et al. Fractalkine: an inflammatory chemokine elevated in subjects with polycystic ovary syndrome. Endocrine. 2019;65:175-83.
